Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Nephrol ; 29(6): 501-8, 2009.
Article in English | MEDLINE | ID: mdl-19060477

ABSTRACT

AIM: We used the USRDS database to test the hypothesis that graft survival was similar using either rabbit antithymocyte globulin (rATG) vs. interleukin-2 receptor inhibitor (IL2i) in the Prograf era. We further explored the variable of race in the two groups of patients. METHODS: We conducted a retrospective cohort study of kidney transplant patients in the USRDS from 2000 through 2005 to compare graft survival (including death) using rATG vs. IL2i with particular reference to outcomes between African-Americans vs. Caucasians. Kaplan-Meier analysis was performed to assess patient and graft survival after transplantation, stratified by recipient induction with rATG versus IL2i. Cox regression analysis was performed to assess adjusted survival after transplantation, assessing whether induction rATG (vs. IL2i) was significant as an interaction term (i.e. an effect modifier) with black race for graft survival. Propensity score analysis was used to address potential confounding by indication. RESULTS: In stratified Cox Regression analysis limited to IL2i, black race was significantly associated with graft loss (adjusted hazard ratio (AHR) 1.17, 95% CI, 1.09-1.26). In analysis limited to rATG induction, black race was not significant (AHR 1.00, 95% CI, 0.92-1.10). We detected a significant interaction between rATG and black race (in comparison with non-black race) for the development of graft loss (AHR, 0.86, 95% CI, 0.76-0.97). Analysis limited to black recipients showed that while use of rATG was not significantly different from IL2i (AHR 0.95, 95% CI 0.87-1.04), the direction of this association was in the opposite direction of non-blacks. CONCLUSIONS: Patient and graft survival were similar in African-American and Caucasian recipients of kidney transplantation using either rATG or IL2i. Limitations of the study are the retrospective nature of USRDS data, center-bias in using rATG vs. IL2i and lack of data on steroid dosage. Results of the present study call for a critical review of induction practices.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Receptors, Interleukin-2/antagonists & inhibitors , Adult , Black or African American , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Antilymphocyte Serum , Basiliximab , Cohort Studies , Daclizumab , Databases, Factual , Female , Graft Rejection/ethnology , Graft Survival , Humans , Immunoglobulin G/pharmacology , Immunoglobulin G/therapeutic use , Immunosuppressive Agents/pharmacology , Male , Middle Aged , Rabbits , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/therapeutic use , Retrospective Studies , United States/epidemiology , White People , Young Adult
2.
Semin Dial ; 20(6): 561-5, 2007.
Article in English | MEDLINE | ID: mdl-17991205

ABSTRACT

Until recently, it was not apparent whether apparent paradoxical associations of body mass index (BMI), lipids, and blood pressure with survival observed in hemodialysis (HD) patients, which contradict observations from the general population, also applied to peritoneal dialysis (PD) patients. Studies of survival in PD patients must account for differences in adjusted survival relative to HD patients, namely, early equivalent to superior survival, but after about 1-2 years, inferior survival. Several recent observational studies have analyzed the association between BMI and survival in PD patients from different perspectives and using different patient populations. In general, these studies found that any survival advantage associated with obesity is significantly less likely in PD than HD patients. Among PD patients, those who are obese can be said to have equivalent survival to PD patients with normal BMI. Studies of lipids and blood pressure in PD patients also yield conflicting associations with survival. Obese patients, especially if diabetic, may have increased risk of death after starting on PD compared to HD, although firm conclusions are premature given the limitations of current evidence. At present, the levels of lipids and blood pressure which are best associated with survival in PD patients are not well-defined.


Subject(s)
Body Mass Index , Peritoneal Dialysis , Epidemiologic Factors , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/pathology , Kidney Failure, Chronic/therapy , Obesity/complications , Peritoneal Dialysis/mortality , Renal Dialysis , Risk Factors , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL